China pharma expects considerable increase in growth opportunities related to hainan free trade port

Haikou, china, april 19, 2021 /prnewswire/ -- china pharma holdings, inc. (nyse american: cphi) ("china pharma," the "company" or "we"), a specialty pharmaceutical company, commented on the policy statements in "several special measures to support the construction of hainan free trade port to relax market access" released by the national development and reform commission and the ministry of commerce in april.  this statement follows the release of the overall plan for the construction of hainan free trade port in june 2020 and the establishment of the hainan boao lecheng international medical tourism pilot district in 2013, which were both approved by the state council.
CPHI Ratings Summary
CPHI Quant Ranking